Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564873 · ClinicalTrials.gov registry record · Phase 1
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
A Phase 1 study of High Grade Myelodysplastic Syndromes, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03564873: Active Phase 1 study of High Grade Myelodysplastic Syndromes, sponsored by University of Colorado, Denver.
NCT03564873 is a Phase 1 study of High Grade Myelodysplastic Syndromes that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03564873, a Phase 1 study of High Grade Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.
Primary Outcome
Determine the recommended dose of omacetaxine based on the maximum tolerated dose.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Omacetaxine
Study Locations (1)
Colorado
- Universtiy of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT03564873 still lists
NCT03564873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with High Grade Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT03564873 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03564873 about?
NCT03564873 is a clinical study titled "Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS". This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.
What is the current status of trial NCT03564873?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-09-17. Estimated completion is 2027-06.
What conditions does trial NCT03564873 study?
This clinical trial studies the following conditions: High Grade Myelodysplastic Syndromes.
What interventions are being tested in trial NCT03564873?
The interventions under investigation include: Azacitidine (DRUG), Omacetaxine (DRUG).
Who is sponsoring clinical trial NCT03564873?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03564873 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03564873's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI